Systemic sclerosis (SSc) carries the highest disease-specific mortality among systemic rheumatic diseases; autologous haematopoietic stem cell transplantation (AHSCT) has emerged as 1 of the disease-modifying treatments for severe, rapidly progressive disease [1–3]. However, real-world data on predictors and patterns of disease reactivation after AHSCT remain limited, and consensus relapse criteria have only recently been proposed [4]. We aimed to characterise the incidence, timing, and clinical features of disease reactivation following AHSCT in SSc.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: